TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2008

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

Patrice Chevallier et al.PubMed ↗Publisher ↗

No numbers read from the abstract.